Publications by authors named "G Steven Bassi"
A search for violation of the charge-parity (CP) symmetry in the D^{+}→K^{-}K^{+}π^{+} decay is presented, with proton-proton collision data corresponding to an integrated luminosity of 5.4 fb^{-1}, collected at a center-of-mass energy of 13 TeV with the LHCb detector. A novel model-independent technique is used to compare the D^{+} and D^{-} phase-space distributions, with instrumental asymmetries subtracted using the D_{s}^{+}→K^{-}K^{+}π^{+} decay as a control channel.
View Article and Find Full Text PDFBackground: In this COVID-19 Critical Care Consortium (CCCC) sub-study, we qualified neurological complications associated with SARS-CoV2 infection.
Methods: The CCCC is an international, multicenter study. Eligible patients were COVID-19 patients admitted to intensive care units (ICU) across 23 centers between 1/7/2020 to 6/23/2022.
This cross-sectional study aimed to identify potential predictors of poor mental health outcomes among healthcare workers in two different waves of the COVID-19 emergency in Italy. An online survey collected data from N = 557 healthcare workers (21-77 years). The study predictors were sociodemographic characteristics, occupational status, factors related to the work environment, COVID-19-related adverse events, and lifetime traumatic events.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted on B^{+} decays to explore resonant structures using data from the LHCb experiment at various energy levels, totaling an integrated luminosity of 9 fb^{-1}.
- The researchers performed a simultaneous amplitude fit on two decay channels, determining the C parities of resonances in the D^{*±}D^{∓} mass spectra.
- Four new charmonium or charmoniumlike states were discovered, including η_{c}(3945) and h_{c}(4000), and the presence of T_{c[over ¯]s[over ¯]0}^{*}(2870)^{0} and T_{c[over ¯]s
Article Synopsis
- Somatostatin receptor type 2 (SSTR2) is commonly found on certain tumors, including gastro-entero-pancreatic neuroendocrine tumors and breast cancer, making it a target for therapy.
- Researchers developed a novel fluorescent-peptide antagonist, Octo-Fluo, that works with genetically engineered CAR T-cells to selectively trigger cell death in SSTR2-expressing cancer cells.
- In laboratory and animal studies, Octo-Fluo enhanced the effectiveness of AdFITC(E2)-CAR T-cells against tumors, but high concentrations of Octo-Fluo could reduce its effectiveness by saturating both the CAR and SSTR2, highlighting the importance of dosage for treatment success.